CareDx, Inc. (NASDAQ:CDNA) Receives Average Rating of “Hold” from Brokerages

Shares of CareDx, Inc. (NASDAQ:CDNA) have earned a consensus rating of “Hold” from the nine research firms that are currently covering the company, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $26.6667.

A number of analysts have commented on the stock. Wells Fargo & Company boosted their price target on shares of CareDx from $14.00 to $18.00 and gave the stock an “equal weight” rating in a research report on Monday, December 15th. Zacks Research upgraded shares of CareDx from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 18th. Wall Street Zen upgraded CareDx from a “hold” rating to a “buy” rating in a research report on Sunday. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of CareDx in a research note on Monday, December 15th. Finally, William Blair initiated coverage on CareDx in a research note on Tuesday, August 26th. They issued a “market perform” rating on the stock.

CareDx Stock Performance

Shares of CDNA stock opened at $19.45 on Monday. CareDx has a 1 year low of $10.96 and a 1 year high of $25.95. The firm has a market capitalization of $1.00 billion, a PE ratio of 16.34 and a beta of 2.54. The stock has a fifty day moving average of $16.69 and a two-hundred day moving average of $15.81.

CareDx (NASDAQ:CDNA) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.15. The company had revenue of $100.06 million for the quarter, compared to analyst estimates of $95.25 million. CareDx had a return on equity of 20.15% and a net margin of 19.65%.The company’s quarterly revenue was up 20.7% compared to the same quarter last year. During the same period last year, the company earned ($0.14) earnings per share. Equities research analysts predict that CareDx will post -0.9 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CareDx

A number of institutional investors and hedge funds have recently bought and sold shares of CDNA. MCF Advisors LLC grew its stake in shares of CareDx by 292.9% in the 2nd quarter. MCF Advisors LLC now owns 1,336 shares of the company’s stock worth $26,000 after purchasing an additional 996 shares during the last quarter. Cetera Trust Company N.A boosted its holdings in CareDx by 11.2% during the second quarter. Cetera Trust Company N.A now owns 12,195 shares of the company’s stock worth $238,000 after buying an additional 1,225 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH grew its position in CareDx by 5.9% in the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 22,509 shares of the company’s stock worth $440,000 after buying an additional 1,264 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in CareDx by 4.8% in the second quarter. The Manufacturers Life Insurance Company now owns 27,742 shares of the company’s stock worth $542,000 after buying an additional 1,280 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey increased its holdings in shares of CareDx by 12.2% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 11,885 shares of the company’s stock valued at $232,000 after buying an additional 1,293 shares in the last quarter.

CareDx Company Profile

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.